

Genetics research in Parkinson's disease has identified over 100 risk loci, yet translating these findings into understanding of disease mechanisms, clinical and pathological heterogeneity, and disease progression remains a challenge. This task requires exploring how genetic risk factors operate over time, interact with environmental factors, and contribute to the diverse ways in which disease manifests. The development of α-synuclein seeding amplification assays (SAAs) offers the opportunity to understand Parkinson's disease pathogenesis and heterogeneity, and drive the development of new disease-modifying and prevention interventions.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet